Literature DB >> 23135268

G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts.

Maria Francesca Santolla1, Rosamaria Lappano, Paola De Marco, Marco Pupo, Adele Vivacqua, Diego Sisci, Sergio Abonante, Domenico Iacopetta, Anna Rita Cappello, Vincenza Dolce, Marcello Maggiolini.   

Abstract

Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many tumors. Fatty acid synthase (FASN) is a key lipogenic enzyme catalyzing the terminal steps in the de novo biogenesis of fatty acids. In cancer cells, FASN may act as a metabolic oncogene, given that it confers growth and survival advantages to these cells, whereas its inhibition effectively and selectively kills tumor cells. Hormones such as estrogens and growth factors contribute to the transcriptional regulation of FASN expression also through the activation of downstream signaling and a cross-talk among diverse transduction pathways. In this study, we demonstrate for the first time that 17β-estradiol (E2) and the selective GPER ligand G-1 regulate FASN expression and activity through the GPER-mediated signaling, which involved the EGF receptor/ERK/c-Fos/AP1 transduction pathway, as ascertained by using specific pharmacological inhibitors, performing gene-silencing experiments and ChIP assays in breast SkBr3, colorectal LoVo, hepatocarcinoma HepG2 cancer cells, and breast cancer-associated fibroblasts. In addition, the proliferative effects induced by E2 and G-1 in these cells involved FASN as the inhibitor of its activity, named cerulenin, abolished the growth response to both ligands. Our data suggest that GPER may be included among the transduction mediators involved by estrogens in regulating FASN expression and activity in cancer cells and cancer-associated fibroblasts that strongly contribute to cancer progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23135268      PMCID: PMC3527911          DOI: 10.1074/jbc.M112.417303

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  64 in total

Review 1.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 2.  Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.

Authors:  F P Kuhajda
Journal:  Nutrition       Date:  2000-03       Impact factor: 4.008

3.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation.

Authors:  Evelien Rysman; Koen Brusselmans; Katryn Scheys; Leen Timmermans; Rita Derua; Sebastian Munck; Paul P Van Veldhoven; David Waltregny; Veerle W Daniëls; Jelle Machiels; Frank Vanderhoydonc; Karine Smans; Etienne Waelkens; Guido Verhoeven; Johannes V Swinnen
Journal:  Cancer Res       Date:  2010-09-28       Impact factor: 12.701

4.  The G protein-coupled receptor 30 is up-regulated by hypoxia-inducible factor-1alpha (HIF-1alpha) in breast cancer cells and cardiomyocytes.

Authors:  Anna Grazia Recchia; Ernestina Marianna De Francesco; Adele Vivacqua; Diego Sisci; Maria Luisa Panno; Sebastiano Andò; Marcello Maggiolini
Journal:  J Biol Chem       Date:  2011-01-25       Impact factor: 5.157

5.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.

Authors:  E J Filardo; J A Quinn; K I Bland; A R Frackelton
Journal:  Mol Endocrinol       Date:  2000-10

6.  Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts.

Authors:  Antonio Madeo; Marcello Maggiolini
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

7.  Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells.

Authors:  Sucharita Bandyopadhyay; Rui Zhan; Ying Wang; Sudha K Pai; Shigeru Hirota; Sadahiro Hosobe; Yukio Takano; Ken Saito; Eiji Furuta; Megumi Iiizumi; Sonia Mohinta; Misako Watabe; Charles Chalfant; Kounosuke Watabe
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  Fatty acid synthase inhibitor cerulenin suppresses liver metastasis of colon cancer in mice.

Authors:  Soichiro Murata; Kazuhiko Yanagisawa; Kiyoshi Fukunaga; Tatsuya Oda; Akihiko Kobayashi; Ryoko Sasaki; Nobuhiro Ohkohchi
Journal:  Cancer Sci       Date:  2010-04-21       Impact factor: 6.716

9.  Estriol acts as a GPR30 antagonist in estrogen receptor-negative breast cancer cells.

Authors:  Rosamaria Lappano; Camillo Rosano; Paola De Marco; Ernestina Marianna De Francesco; Vincenzo Pezzi; Marcello Maggiolini
Journal:  Mol Cell Endocrinol       Date:  2010-02-06       Impact factor: 4.102

10.  c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells.

Authors:  A Madeo; M Vinciguerra; R Lappano; M Galgani; A Gasperi-Campani; M Maggiolini; A M Musti
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more
  42 in total

1.  Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor.

Authors:  Yun Teng; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2014-05-17       Impact factor: 4.102

Review 2.  Metabolism of stromal and immune cells in health and disease.

Authors:  Bart Ghesquière; Brian W Wong; Anna Kuchnio; Peter Carmeliet
Journal:  Nature       Date:  2014-07-10       Impact factor: 49.962

Review 3.  Immunometabolism: A new target for improving cancer immunotherapy.

Authors:  Chunqing Guo; Shixian Chen; Wenjie Liu; Yibao Ma; Juan Li; Paul B Fisher; Xianjun Fang; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 4.  GPER modulators: Opportunity Nox on the heels of a class Akt.

Authors:  Eric R Prossnitz
Journal:  J Steroid Biochem Mol Biol       Date:  2017-03-08       Impact factor: 4.292

5.  Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway.

Authors:  Ligong Chang; Peng Wu; Ravichandran Senthilkumar; Xiaoqiang Tian; Hui Liu; Xia Shen; Zijian Tao; Peilin Huang
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-25       Impact factor: 4.553

6.  Estrogen Enhances Linkage in the Vascular Endothelial Calmodulin Network via a Feedforward Mechanism at the G Protein-coupled Estrogen Receptor 1.

Authors:  Quang-Kim Tran; Rachel Firkins; Jennifer Giles; Sarah Francis; Vahe Matnishian; Phuong Tran; Mark VerMeer; Jake Jasurda; Michelle Ann Burgard; Briana Gebert-Oberle
Journal:  J Biol Chem       Date:  2016-03-17       Impact factor: 5.157

7.  Cell contact and Nf2/Merlin-dependent regulation of TEAD palmitoylation and activity.

Authors:  Nam-Gyun Kim; Barry M Gumbiner
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-01       Impact factor: 11.205

8.  Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells.

Authors:  Yun Teng; Brandie N Radde; Lacey M Litchfield; Margarita M Ivanova; Russell A Prough; Barbara J Clark; Mark A Doll; David W Hein; Carolyn M Klinge
Journal:  J Biol Chem       Date:  2015-05-11       Impact factor: 5.157

9.  Evaluating estradiol levels in male patients with colorectal carcinoma.

Authors:  Atreyee Basu; Shashi Seth; Kanchan Arora; Monica Verma
Journal:  J Clin Diagn Res       Date:  2015-01-01

Review 10.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.